itraconazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
systemic antifungal agents, miconazole derivatives	1513	84625-61-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: itraconazole canditral itrizole oriconazole traconal triasporin R-51211	A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis. Molecular weight: 705.64 Formula: C35H38Cl2N8O4 CLOGP: 6.84 LIPINSKI: 3 HAC: 12 HDO: 0 TPSA: 100.79 ALOGS: -4.86 ROTB: 11 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

itraconazole
canditral
itrizole
oriconazole
traconal
triasporin
R-51211

A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.

Molecular weight: 705.64
Formula: C35H38Cl2N8O4
CLOGP: 6.84
LIPINSKI: 3
HAC: 12
HDO: 0
TPSA: 100.79
ALOGS: -4.86
ROTB: 11

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.20	g	O
0.20	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.03 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	14.17 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	55 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	7.40 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	5.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.00 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	25 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Sept. 11, 1992	FDA	JANSSEN PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	370.87	15.77	323	11751	228808	63248140
Febrile neutropenia	129.78	15.77	135	11939	118314	63358634
Aspergillus infection	129.17	15.77	51	12023	8042	63468906
Bronchopulmonary aspergillosis	122.54	15.77	50	12024	8585	63468363
Pseudohyponatraemia	103.86	15.77	16	12058	31	63476917
Symmetrical drug-related intertriginous and flexural exanthema	92.29	15.77	21	12053	483	63476465
Drug resistance	81.34	15.77	52	12022	22881	63454067
Rhabdomyolysis	74.77	15.77	64	12010	43887	63433061
Neutrophil count decreased	68.44	15.77	68	12006	56338	63420610
Myopathy	65.18	15.77	35	12039	11156	63465792
Hepatic function abnormal	65.04	15.77	55	12019	37087	63439861
Pseudoaldosteronism	62.15	15.77	11	12063	64	63476884
Cytomegalovirus test positive	58.81	15.77	22	12052	2996	63473952
Cytomegalovirus infection	54	15.77	39	12035	20913	63456035
Pathogen resistance	51.81	15.77	25	12049	6373	63470575
Labelled drug-drug interaction medication error	51.56	15.77	32	12042	13367	63463581
Skin candida	51.14	15.77	17	12057	1638	63475310
Pain	50.92	15.77	40	12034	740588	62736360
Sepsis	50.24	15.77	98	11976	153025	63323923
Neutropenia	47.99	15.77	104	11970	174901	63302047
Adrenal suppression	47.47	15.77	14	12060	910	63476038
Acute graft versus host disease	47.40	15.77	21	12053	4407	63472541
Acute myeloid leukaemia	46.68	15.77	33	12041	17114	63459834
Platelet count decreased	46.50	15.77	81	11993	116041	63360907
Septic shock	46.07	15.77	60	12014	66569	63410379
Histoplasmosis disseminated	45.17	15.77	15	12059	1441	63475507
Fungal endocarditis	43.82	15.77	10	12064	233	63476715
Abdominal discomfort	43.65	15.77	5	12069	320880	63156068
Hypokalaemia	43.65	15.77	74	12000	103730	63373218
Trichosporon infection	41.99	15.77	10	12064	282	63476666
Adrenal insufficiency	40.89	15.77	31	12043	17884	63459064
Transplant rejection	39.60	15.77	25	12049	10755	63466193
Neutropenic sepsis	38.75	15.77	29	12045	16409	63460539
Contraindicated product prescribed	38.52	15.77	13	12061	1312	63475636
Cardiotoxicity	37.22	15.77	22	12052	8416	63468532
Liver disorder	36.57	15.77	48	12026	53639	63423309
Acute graft versus host disease in skin	35.76	15.77	16	12058	3436	63473512
Corneal perforation	35.75	15.77	10	12064	538	63476410
Scedosporium infection	35.48	15.77	10	12064	553	63476395
Lung transplant rejection	34.65	15.77	11	12063	916	63476032
Pneumonia fungal	34.42	15.77	18	12056	5437	63471511
Thrombocytopenia	33.88	15.77	83	11991	151074	63325874
Cytomegalovirus viraemia	33.82	15.77	18	12056	5631	63471317
Pneumonia	32.67	15.77	172	11902	456595	63020353
Fatigue	32.56	15.77	76	11998	887952	62588996
Drug level increased	32.46	15.77	30	12044	22706	63454242
Pleural effusion	32.19	15.77	61	12013	93149	63383799
Ileus paralytic	31.55	15.77	16	12058	4535	63472413
Swelling	31.37	15.77	7	12067	275371	63201577
Disseminated intravascular coagulation	30.88	15.77	27	12047	19024	63457924
Immune reconstitution inflammatory syndrome associated tuberculosis	29.94	15.77	8	12066	362	63476586
Electrocardiogram QT prolonged	29.86	15.77	46	12028	59484	63417464
Human herpesvirus 6 infection reactivation	29.86	15.77	8	12066	366	63476582
White blood cell count decreased	29.71	15.77	75	11999	139029	63337919
Fungal infection	28.31	15.77	35	12039	36839	63440109
Rheumatoid arthritis	27.82	15.77	7	12067	253812	63223136
Joint swelling	27.51	15.77	14	12060	327652	63149296
Posterior reversible encephalopathy syndrome	26.95	15.77	24	12050	17321	63459627
Systemic lupus erythematosus	26.60	15.77	4	12070	208914	63268034
Infective pulmonary exacerbation of cystic fibrosis	26.41	15.77	18	12056	8799	63468149
Eye infection fungal	26.37	15.77	6	12068	138	63476810
Pyrexia	26.31	15.77	166	11908	470312	63006636
Multiple organ dysfunction syndrome	25.90	15.77	42	12032	56710	63420238
Graft versus host disease	25.63	15.77	16	12058	6747	63470201
Liver function test abnormal	25.25	15.77	38	12036	48143	63428805
Respiratory failure	25.04	15.77	58	12016	101800	63375148
Blood lactate dehydrogenase increased	24.63	15.77	26	12048	23090	63453858
Cardiac failure	24.42	15.77	53	12021	89089	63387859
Erythema multiforme	24.10	15.77	18	12056	10151	63466797
Cystic fibrosis	24.06	15.77	12	12062	3284	63473664
Moraxella infection	23.96	15.77	7	12067	440	63476508
Cholestatic liver injury	23.58	15.77	11	12063	2599	63474349
Candida infection	23.54	15.77	28	12046	28323	63448625
Oedema	23.35	15.77	55	12019	97567	63379381
Varicella zoster virus infection	23.27	15.77	11	12063	2678	63474270
Duplicate therapy error	22.98	15.77	5	12069	93	63476855
Arthropathy	22.95	15.77	8	12066	234784	63242164
Immunosuppressant drug level increased	22.94	15.77	12	12062	3626	63473322
Pancreatitis haemorrhagic	22.75	15.77	7	12067	526	63476422
Duodenal atresia	22.70	15.77	3	12071	0	63476948
Cross sensitivity reaction	22.33	15.77	10	12064	2152	63474796
Drug hypersensitivity	22.26	15.77	16	12058	310671	63166277
Klebsiella infection	22.19	15.77	16	12058	8550	63468398
Cardiac valve vegetation	22.13	15.77	6	12068	287	63476661
Therapeutic product effect decreased	21.81	15.77	5	12069	193182	63283766
Discomfort	21.78	15.77	3	12071	167371	63309577
Implant site hypersensitivity	21.60	15.77	4	12070	31	63476917
Thrombotic microangiopathy	21.33	15.77	17	12057	10544	63466404
Systemic mycosis	20.71	15.77	8	12066	1189	63475759
Arthralgia	20.61	15.77	49	12025	569661	62907287
Blood prolactin increased	20.52	15.77	11	12063	3492	63473456
Pseudomonas infection	20.43	15.77	17	12057	11196	63465752
Musculoskeletal stiffness	20.40	15.77	5	12069	184613	63292335
Product dispensing issue	20.04	15.77	5	12069	172	63476776
Blast cell count increased	19.64	15.77	6	12068	440	63476508
Mucormycosis	19.63	15.77	10	12064	2861	63474087
Disseminated varicella zoster vaccine virus infection	19.59	15.77	4	12070	54	63476894
Myositis	18.89	15.77	15	12059	9251	63467697
Cystitis haemorrhagic	18.84	15.77	11	12063	4112	63472836
Trichophytosis	18.78	15.77	4	12070	67	63476881
Galactorrhoea	18.76	15.77	11	12063	4144	63472804
Hypersensitivity	18.56	15.77	17	12057	292668	63184280
Ecchymosis	18.53	15.77	16	12058	11078	63465870
Fall	18.29	15.77	29	12045	392305	63084643
Exposure during pregnancy	18.24	15.77	68	12006	155479	63321469
Mucosal inflammation	17.81	15.77	32	12042	46896	63430052
Hypogammaglobulinaemia	17.71	15.77	13	12061	7142	63469806
Oedema peripheral	17.57	15.77	77	11997	189434	63287514
Conjunctival haemorrhage	17.54	15.77	10	12064	3577	63473371
Culture stool positive	17.39	15.77	5	12069	297	63476651
Alanine aminotransferase increased	17.20	15.77	51	12023	103719	63373229
Infusion related reaction	17.12	15.77	13	12061	245508	63231440
Cushing's syndrome	17.09	15.77	6	12068	681	63476267
Renal failure	16.89	15.77	55	12019	117597	63359351
Product dose omission issue	16.86	15.77	12	12062	234301	63242647
Engraft failure	16.44	15.77	5	12069	361	63476587
Staphylococcal sepsis	16.23	15.77	13	12061	8115	63468833
Maternal exposure during pregnancy	16.19	15.77	11	12063	220051	63256897
Drug-induced liver injury	16.00	15.77	28	12046	40194	63436754
Pneumonia cytomegaloviral	15.98	15.77	8	12066	2206	63474742

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	212.40	14.56	360	14593	225586	34716392
Aspergillus infection	132.64	14.56	76	14877	12178	34929800
Drug resistance	101.43	14.56	86	14867	25841	34916137
Bronchopulmonary aspergillosis	98.11	14.56	67	14886	14592	34927386
Febrile neutropenia	92.82	14.56	190	14763	136659	34805319
Pathogen resistance	92.54	14.56	55	14898	9427	34932551
Fungal infection	77.41	14.56	60	14893	15875	34926103
Cardiotoxicity	74.74	14.56	40	14913	5608	34936370
Neutrophil count decreased	72.60	14.56	99	14854	51005	34890973
Parathyroid gland enlargement	71.65	14.56	16	14937	141	34941837
Upper respiratory fungal infection	70.10	14.56	16	14937	157	34941821
Platelet count decreased	66.02	14.56	153	14800	119564	34822414
Bronchopulmonary aspergillosis allergic	58.78	14.56	20	14933	909	34941069
Forced expiratory volume	58.37	14.56	13	14940	113	34941865
Drug level increased	56.76	14.56	58	14895	22038	34919940
Drug ineffective	55.08	14.56	358	14595	456393	34485585
Hepatic function abnormal	54.21	14.56	80	14873	44283	34897695
Cytomegalovirus test positive	52.76	14.56	28	14925	3858	34938120
Phaeohyphomycosis	52.32	14.56	18	14935	846	34941132
Hypokalaemia	46.87	14.56	87	14866	58127	34883851
Mycobacterial infection	43.64	14.56	21	14932	2353	34939625
Cytomegalovirus infection	42.29	14.56	54	14899	26081	34915897
Bronchiectasis	41.39	14.56	34	14919	9767	34932211
Acute myeloid leukaemia recurrent	39.30	14.56	19	14934	2151	34939827
Disseminated intravascular coagulation	38.37	14.56	47	14906	21769	34920209
Histoplasmosis disseminated	37.59	14.56	16	14937	1347	34940631
Fluorosis	37.58	14.56	8	14945	55	34941923
Bronchial disorder	37.14	14.56	16	14937	1387	34940591
Granulomatous rosacea	35.21	14.56	9	14944	147	34941831
White blood cell count decreased	35.15	14.56	105	14848	95340	34846638
Renal impairment	34.83	14.56	104	14849	94409	34847569
Tendon disorder	34.26	14.56	19	14934	2856	34939122
Blood lactate dehydrogenase increased	33.31	14.56	45	14908	22945	34919033
Fatigue	33.26	14.56	68	14885	370585	34571393
Obliterative bronchiolitis	32.22	14.56	14	14939	1239	34940739
Pseudoaldosteronism	30.55	14.56	7	14946	70	34941908
Secretion discharge	30.35	14.56	23	14930	5882	34936096
Philadelphia positive acute lymphocytic leukaemia	30.15	14.56	6	14947	28	34941950
Pyrexia	30.12	14.56	244	14709	332769	34609209
Obstructive airways disorder	29.90	14.56	35	14918	15459	34926519
Adrenal insufficiency	29.24	14.56	33	14920	14014	34927964
Sinus congestion	29.18	14.56	22	14931	5583	34936395
Hyperventilation	29.17	14.56	17	14936	2807	34939171
Pseudomonas infection	29.09	14.56	31	14922	12351	34929627
Myopathy	29.06	14.56	30	14923	11524	34930454
Acute graft versus host disease	28.38	14.56	23	14930	6480	34935498
Apparent mineralocorticoid excess	28.34	14.56	6	14947	40	34941938
Haemoptysis	27.76	14.56	52	14901	34954	34907024
Lung transplant rejection	27.63	14.56	11	14942	781	34941197
Death	27.17	14.56	84	14869	397965	34544013
Lip squamous cell carcinoma	26.80	14.56	7	14946	125	34941853
Pneumonia fungal	26.62	14.56	23	14930	7077	34934901
Neutrophil Pelger-Huet anomaly present	26.47	14.56	8	14945	247	34941731
Acute graft versus host disease in skin	26.16	14.56	20	14933	5181	34936797
Ileus paralytic	25.73	14.56	21	14932	5976	34936002
Ocular surface squamous neoplasia	25.55	14.56	5	14948	21	34941957
Pneumonia	25.23	14.56	251	14702	362376	34579602
Graft versus host disease	24.02	14.56	26	14927	10543	34931435
Symmetrical drug-related intertriginous and flexural exanthema	23.82	14.56	8	14945	349	34941629
Sputum increased	23.78	14.56	14	14939	2356	34939622
Cerebrovascular accident	23.49	14.56	4	14949	84807	34857171
Blood immunoglobulin E increased	22.85	14.56	14	14939	2532	34939446
Drug abuse	22.82	14.56	7	14946	99089	34842889
Cystitis haemorrhagic	22.52	14.56	19	14934	5660	34936318
Asthma-chronic obstructive pulmonary disease overlap syndrome	22.50	14.56	11	14942	1276	34940702
Capillaritis	22.47	14.56	6	14947	117	34941861
Cardiovascular insufficiency	22.46	14.56	12	14941	1675	34940303
Polyomavirus-associated nephropathy	22.06	14.56	16	14937	3828	34938150
Neutropenia	21.93	14.56	128	14825	156650	34785328
Folliculitis	21.75	14.56	17	14936	4549	34937429
Trichosporon infection	21.52	14.56	9	14944	725	34941253
Ubiquinone decreased	21.49	14.56	4	14949	12	34941966
Liver disorder	21.32	14.56	45	14908	32952	34909026
Myositis	21.21	14.56	26	14927	12044	34929934
Transplant rejection	21.08	14.56	24	14929	10287	34931691
Fall	21.02	14.56	34	14919	202851	34739127
COVID-19	20.74	14.56	4	14949	77546	34864432
Product dose omission issue	20.43	14.56	13	14940	119698	34822280
Cytomegalovirus viraemia	19.98	14.56	20	14933	7410	34934568
CARD9 deficiency	19.87	14.56	4	14949	20	34941958
Lymphadenopathy	19.78	14.56	40	14913	28423	34913555
Respiratory disorder	19.67	14.56	32	14921	19232	34922746
Pain	19.65	14.56	36	14917	204639	34737339
Acute graft versus host disease in intestine	19.60	14.56	13	14940	2695	34939283
Squamous cell carcinoma of the oral cavity	19.03	14.56	6	14947	214	34941764
Candida infection	18.87	14.56	30	14923	17685	34924293
Contraindicated product prescribed	18.87	14.56	7	14946	410	34941568
Post transplant lymphoproliferative disorder	18.34	14.56	18	14935	6510	34935468
Acute myeloid leukaemia	18.19	14.56	30	14923	18240	34923738
Acute graft versus host disease in liver	17.71	14.56	10	14943	1556	34940422
Feeling abnormal	17.47	14.56	3	14950	63232	34878746
Oedema	17.46	14.56	51	14902	45690	34896288
Dizziness	17.17	14.56	43	14910	218478	34723500
Neuropathy peripheral	16.52	14.56	75	14878	83188	34858790
Aspergilloma	16.52	14.56	6	14947	331	34941647
Aspartate aminotransferase increased	16.51	14.56	65	14888	67718	34874260
Pulmonary haemorrhage	16.20	14.56	21	14932	10283	34931695
Drug level changed	16.07	14.56	6	14947	358	34941620
Sepsis	16.05	14.56	124	14829	166437	34775541
Epstein-Barr virus infection	16.01	14.56	18	14935	7610	34934368
Pneumonia cytomegaloviral	15.92	14.56	12	14941	3042	34938936
Adrenal suppression	15.89	14.56	7	14946	640	34941338
Differentiation syndrome	15.77	14.56	9	14944	1429	34940549
Multiple-drug resistance	15.76	14.56	15	14938	5224	34936754
Lung disorder	15.53	14.56	41	14912	34655	34907323
Alanine aminotransferase increased	15.44	14.56	72	14881	80743	34861235
Overdose	15.38	14.56	10	14943	91049	34850929
Condition aggravated	15.28	14.56	137	14816	192059	34749919
Pleural effusion	15.11	14.56	72	14881	81474	34860504
Back pain	15.01	14.56	18	14935	121771	34820207
Cushingoid	14.90	14.56	11	14942	2703	34939275
Hyperhidrosis	14.68	14.56	7	14946	75685	34866293
Pseudomembranous colitis	14.63	14.56	11	14942	2780	34939198

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	511.10	13.86	623	23235	414560	79305970
Aspergillus infection	232.84	13.86	114	23744	19047	79701483
Bronchopulmonary aspergillosis	199.61	13.86	108	23750	22186	79698344
Drug resistance	174.43	13.86	125	23733	42088	79678442
Febrile neutropenia	162.44	13.86	266	23592	230733	79489797
Pathogen resistance	161.39	13.86	81	23777	14261	79706269
Neutrophil count decreased	113.14	13.86	140	23718	93819	79626711
Cardiotoxicity	111.51	13.86	60	23798	12179	79708351
Symmetrical drug-related intertriginous and flexural exanthema	107.44	13.86	29	23829	857	79719673
Ileus paralytic	101.42	13.86	52	23806	9568	79710962
Myopathy	92.12	13.86	64	23794	20499	79700031
Platelet count decreased	90.91	13.86	188	23670	194476	79526054
Drug level increased	88.50	13.86	82	23776	39569	79680961
Pseudoaldosteronism	87.08	13.86	18	23840	158	79720372
Hepatic function abnormal	83.31	13.86	106	23752	73001	79647529
Fungal infection	81.15	13.86	80	23778	41668	79678862
Pseudohyponatraemia	79.52	13.86	16	23842	121	79720409
Hypokalaemia	74.25	13.86	145	23713	143895	79576635
Cytomegalovirus test positive	71.07	13.86	35	23823	5912	79714618
Phaeohyphomycosis	68.96	13.86	22	23836	1175	79719355
Pain	66.13	13.86	68	23790	703734	79016796
Fatigue	65.78	13.86	111	23747	929616	78790914
Cytomegalovirus infection	65.43	13.86	72	23786	42572	79677958
Parathyroid gland enlargement	64.46	13.86	14	23844	159	79720371
Histoplasmosis disseminated	61.41	13.86	24	23834	2329	79718201
Completed suicide	61.04	13.86	3	23855	245764	79474766
Drug ineffective	60.73	13.86	539	23319	1080374	78640156
Lung transplant rejection	59.80	13.86	21	23837	1510	79719020
Forced expiratory volume	58.93	13.86	12	23846	97	79720433
Adrenal suppression	57.76	13.86	20	23838	1379	79719151
Pneumonia fungal	57.62	13.86	38	23820	11172	79709358
Transplant rejection	57.07	13.86	47	23811	19390	79701140
Granulomatous rosacea	56.02	13.86	13	23845	203	79720327
Trichosporon infection	55.91	13.86	18	23840	990	79719540
Rhabdomyolysis	54.56	13.86	105	23753	103026	79617504
Upper respiratory fungal infection	54.45	13.86	14	23844	341	79720189
Contraindicated product prescribed	53.71	13.86	20	23838	1701	79718829
Pneumonia	52.96	13.86	358	23500	659888	79060642
Adrenal insufficiency	52.42	13.86	53	23805	28434	79692096
White blood cell count decreased	51.47	13.86	148	23710	188140	79532390
Skin candida	49.97	13.86	20	23838	2067	79718463
Bronchopulmonary aspergillosis allergic	48.86	13.86	22	23836	3039	79717491
Blood lactate dehydrogenase increased	48.13	13.86	59	23799	39111	79681419
Pleural effusion	47.52	13.86	122	23736	145140	79575390
Acute graft versus host disease in skin	46.92	13.86	29	23829	7629	79712901
Labelled drug-drug interaction medication error	46.47	13.86	49	23809	27601	79692929
Acute myeloid leukaemia	45.40	13.86	51	23807	30834	79689696
Rheumatoid arthritis	44.82	13.86	5	23853	208465	79512065
Fluorosis	44.59	13.86	10	23848	133	79720397
Pseudomonas infection	44.27	13.86	42	23816	20861	79699669
Acute myeloid leukaemia recurrent	43.70	13.86	21	23837	3362	79717168
Graft versus host disease	43.41	13.86	36	23822	14990	79705540
Cytomegalovirus viraemia	41.87	13.86	33	23825	12788	79707742
Bronchiectasis	41.83	13.86	42	23816	22344	79698186
Acute graft versus host disease	41.72	13.86	30	23828	10137	79710393
Myositis	41.52	13.86	39	23819	19129	79701401
Drug hypersensitivity	41.10	13.86	19	23839	298897	79421633
Disseminated intravascular coagulation	40.86	13.86	52	23806	35790	79684740
Abdominal discomfort	39.31	13.86	13	23845	250714	79469816
Mycobacterial infection	39.16	13.86	20	23838	3648	79716882
Sepsis	39.14	13.86	172	23686	269256	79451274
Pyrexia	38.71	13.86	340	23518	678369	79042161
Joint swelling	38.69	13.86	19	23839	288627	79431903
Liver disorder	38.62	13.86	74	23784	72343	79648187
Renal impairment	38.34	13.86	119	23739	157664	79562866
Fungal endocarditis	38.34	13.86	12	23846	602	79719928
Neutropenia	37.58	13.86	178	23680	287532	79432998
Cystitis haemorrhagic	37.49	13.86	27	23831	9145	79711385
Candida pneumonia	37.12	13.86	12	23846	669	79719861
Fall	36.44	13.86	56	23802	487573	79232957
Septic shock	35.96	13.86	99	23759	122702	79597828
Musculoskeletal stiffness	35.66	13.86	5	23853	175003	79545527
Respiratory failure	35.55	13.86	127	23731	180784	79539746
Product dose omission issue	35.18	13.86	15	23843	247522	79473008
Cardiac failure	35.08	13.86	114	23744	154728	79565802
Sputum increased	34.86	13.86	20	23838	4593	79715937
Neuropathy peripheral	34.73	13.86	107	23751	141198	79579332
Swelling	34.38	13.86	11	23847	216700	79503830
Candida infection	33.77	13.86	49	23809	38165	79682365
Obliterative bronchiolitis	33.76	13.86	17	23841	3011	79717519
Dizziness	33.41	13.86	67	23791	526374	79194156
Oedema	32.65	13.86	94	23764	119486	79601044
Blast cell count increased	31.99	13.86	13	23845	1397	79719133
Arthropathy	31.86	13.86	7	23851	177104	79543426
Scedosporium infection	31.40	13.86	13	23845	1465	79719065
Bronchial disorder	30.79	13.86	15	23843	2474	79718056
Arthralgia	30.44	13.86	80	23778	571723	79148807
Aspergilloma	29.94	13.86	10	23848	618	79719912
Apparent mineralocorticoid excess	29.86	13.86	6	23852	45	79720485
Headache	29.38	13.86	99	23759	653673	79066857
Acute graft versus host disease in intestine	29.15	13.86	17	23841	4024	79716506
Corneal perforation	28.03	13.86	10	23848	753	79719777
Philadelphia positive acute lymphocytic leukaemia	27.88	13.86	6	23852	65	79720465
Infective pulmonary exacerbation of cystic fibrosis	27.55	13.86	26	23832	12825	79707705
Haemoptysis	27.16	13.86	55	23803	55944	79664586
Ocular surface squamous neoplasia	26.97	13.86	5	23853	23	79720507
Infusion related reaction	26.78	13.86	18	23840	230219	79490311
Therapeutic product effect decreased	26.56	13.86	8	23850	163855	79556675
Neutrophil Pelger-Huet anomaly present	26.42	13.86	8	23850	359	79720171
Post transplant lymphoproliferative disorder	26.13	13.86	24	23834	11440	79709090
Mucormycosis	25.95	13.86	21	23837	8448	79712082
Pneumonia cytomegaloviral	25.92	13.86	17	23841	4952	79715578
Systemic lupus erythematosus	25.79	13.86	3	23855	121146	79599384
Injection site pain	25.78	13.86	4	23854	129834	79590696
Cushingoid	25.77	13.86	22	23836	9530	79711000
Blood immunoglobulin E increased	25.62	13.86	18	23840	5864	79714666
Peripheral swelling	25.29	13.86	26	23832	269591	79450939
Pneumonia bacterial	25.18	13.86	30	23828	19301	79701229
Liver function test abnormal	25.17	13.86	58	23800	64417	79656113
Drug level decreased	25.05	13.86	26	23832	14376	79706154
Alanine aminotransferase increased	24.51	13.86	105	23753	162465	79558065
Polyomavirus-associated nephropathy	24.00	13.86	17	23841	5610	79714920
Toxicity to various agents	23.95	13.86	57	23801	421483	79299047
Product use in unapproved indication	23.83	13.86	142	23716	250217	79470313
Electrocardiogram QT prolonged	23.66	13.86	70	23788	90316	79630214
Eye infection fungal	23.54	13.86	8	23850	521	79720009
Lip squamous cell carcinoma	23.32	13.86	7	23851	305	79720225
Multiple organ dysfunction syndrome	23.25	13.86	84	23774	120162	79600368
Lower respiratory tract infection fungal	22.97	13.86	9	23849	879	79719651
Human herpesvirus 6 infection reactivation	22.89	13.86	8	23850	567	79719963
Back pain	22.63	13.86	35	23823	304145	79416385
Cross sensitivity reaction	22.59	13.86	14	23844	3698	79716832
Fusarium infection	22.54	13.86	11	23847	1821	79718709
Discomfort	22.52	13.86	5	23853	125612	79594918
Tendon disorder	22.40	13.86	18	23840	7168	79713362
Pulmonary alveolar haemorrhage	22.34	13.86	22	23836	11435	79709095
Immune reconstitution inflammatory syndrome	22.32	13.86	24	23834	13817	79706713
Tumour lysis syndrome	21.60	13.86	31	23827	23908	79696622
Systemic mycosis	21.33	13.86	12	23846	2654	79717876
CARD9 deficiency	21.30	13.86	4	23854	20	79720510
Myelosuppression	21.26	13.86	41	23817	40255	79680275
Acute lymphocytic leukaemia	21.16	13.86	15	23843	4954	79715576
Lung infiltration	21.15	13.86	30	23828	22882	79697648
Immunosuppressant drug level increased	20.77	13.86	19	23839	9008	79711522
Obstructive airways disorder	20.39	13.86	35	23823	31424	79689106
Varicella zoster virus infection	20.30	13.86	14	23844	4427	79716103
Hyperhidrosis	20.24	13.86	10	23848	151482	79569048
Cardiovascular insufficiency	20.09	13.86	12	23846	2969	79717561
Blood creatine phosphokinase increased	20.05	13.86	54	23804	66036	79654494
Implant site hypersensitivity	20.03	13.86	4	23854	29	79720501
Ubiquinone decreased	20.03	13.86	4	23854	29	79720501
Immune reconstitution inflammatory syndrome associated tuberculosis	19.97	13.86	8	23850	828	79719702
Histoplasmosis	19.89	13.86	11	23847	2354	79718176
Hypersensitivity	19.67	13.86	30	23828	262209	79458321
Capillaritis	19.57	13.86	6	23852	281	79720249
Disseminated varicella zoster vaccine virus infection	19.56	13.86	5	23853	119	79720411
Cytomegalovirus infection reactivation	19.39	13.86	18	23840	8698	79711832
Differentiation syndrome	19.22	13.86	11	23847	2513	79718017
Acute graft versus host disease in liver	19.07	13.86	10	23848	1925	79718605
Secretion discharge	19.05	13.86	23	23835	14999	79705531
Aspartate aminotransferase increased	18.97	13.86	87	23771	138554	79581976
Burkholderia cepacia complex infection	18.96	13.86	6	23852	312	79720218
Jaundice	18.67	13.86	46	23812	53303	79667227
Cushing's syndrome	18.63	13.86	8	23850	987	79719543
Oedema peripheral	18.47	13.86	134	23724	252154	79468376
Chronic granulomatous disease	18.45	13.86	4	23854	45	79720485
Moraxella infection	18.42	13.86	7	23851	630	79719900
Thrombocytopenia	18.34	13.86	139	23719	265120	79455410
Pseudomonal sepsis	18.27	13.86	15	23843	6159	79714371
Cerebrovascular accident	18.24	13.86	12	23846	155280	79565250
Periostitis	18.18	13.86	7	23851	653	79719877
Cortisol decreased	17.99	13.86	10	23848	2162	79718368
Arthritis	17.91	13.86	6	23852	114874	79605656
Bone marrow failure	17.81	13.86	44	23814	51063	79669467
Staphylococcal sepsis	17.79	13.86	22	23836	14704	79705826
Trichophytosis	17.76	13.86	6	23852	384	79720146
Corneal epithelium defect	17.59	13.86	7	23851	712	79719818
COVID-19	17.44	13.86	13	23845	157661	79562869
Multiple-drug resistance	17.33	13.86	17	23841	8791	79711739
Cystic fibrosis	17.19	13.86	12	23846	3868	79716662
Neurotoxicity	17.05	13.86	33	23825	32485	79688045
Chronic graft versus host disease	17.04	13.86	15	23843	6766	79713764
Product dispensing issue	16.92	13.86	5	23853	206	79720324
Asthma-chronic obstructive pulmonary disease overlap syndrome	16.75	13.86	11	23847	3210	79717320
Klebsiella infection	16.65	13.86	22	23836	15698	79704832
Pancreatitis haemorrhagic	16.62	13.86	7	23851	823	79719707
Squamous cell carcinoma of the oral cavity	15.98	13.86	6	23852	522	79720008
Septic embolus	15.79	13.86	9	23849	2042	79718488
Contusion	15.53	13.86	13	23845	148763	79571767
BK virus infection	15.50	13.86	16	23842	8788	79711742
Drug level changed	15.48	13.86	6	23852	569	79719961
Maternal exposure during pregnancy	15.44	13.86	11	23847	136527	79584003
Pericarditis	15.31	13.86	6	23852	104230	79616300
Psoriasis	15.21	13.86	4	23854	89583	79630947
Haemophagocytic lymphohistiocytosis	15.09	13.86	25	23833	21812	79698718
Hypogammaglobulinaemia	15.09	13.86	19	23839	12932	79707598
Hyperventilation	15.09	13.86	15	23843	7884	79712646
Duplicate therapy error	15.08	13.86	5	23853	302	79720228
Migraine	14.67	13.86	4	23854	87489	79633041
Stress	14.61	13.86	3	23855	79609	79640921
Alternaria infection	14.49	13.86	6	23852	676	79719854
Graft versus host disease in skin	14.40	13.86	13	23845	6060	79714470
Atypical mycobacterial infection	14.37	13.86	8	23850	1735	79718795
Disease recurrence	14.35	13.86	37	23821	44072	79676458
Blood bilirubin increased	14.30	13.86	48	23810	66184	79654346
Injection site erythema	14.24	13.86	3	23855	78194	79642336
Engraft failure	14.23	13.86	6	23852	707	79719823
Ecchymosis	14.17	13.86	20	23838	15186	79705344
Sinus congestion	14.05	13.86	23	23835	19873	79700657
Respiratory disorder	13.96	13.86	37	23821	44819	79675711
Enterobacter pneumonia	13.93	13.86	4	23854	149	79720381
Overdose	13.87	13.86	21	23837	184185	79536345
Pain in extremity	13.87	13.86	59	23799	364479	79356051
Iron overload	13.87	13.86	8	23850	1856	79718674

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J02AC02	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE Triazole and tetrazole derivatives
FDA CS	M0002083	Azoles
FDA EPC	N0000175487	Azole Antifungal
CHEBI has role	CHEBI:50183	P450 inhibitors
CHEBI has role	CHEBI:77748	steroid-transporting ATPase inhibitor
CHEBI has role	CHEBI:140921	Hedgehog pathway inhibitors
FDA MoA	N0000182141	Cytochrome P450 3A4 Inhibitors
FDA MoA	N0000185503	P-Glycoprotein Inhibitors
FDA MoA	N0000190113	Breast Cancer Resistance Protein Inhibitors
MeSH PA	D058888	14-alpha Demethylase Inhibitors
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000935	Antifungal Agents
MeSH PA	D065692	Cytochrome P-450 CYP3A Inhibitors
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D065088	Steroid Synthesis Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Invasive pulmonary aspergillosis	indication	3214003
Histoplasmosis	indication	12962009	DOID:1731
Candidiasis of the esophagus	indication	20639004	DOID:13146
Fusarium infection	indication	64250002
Aspergillosis	indication	65553006	DOID:13564
Blastomycosis	indication	69996000	DOID:12663
Disseminated candidiasis	indication	70572005
Onychomycosis of fingernails	indication	403058003
Onychomycosis of toenails	indication	403059006
Candidemia	indication	432261003
Fungal Infection due to Scedosporium Apiospermum	indication
Fungal Infection due to Fusarium Solani	indication
Oropharyngeal Candidiasis	indication
Coccidioidomycosis	off-label use	60826002	DOID:13450
Chromoblastomycosis	off-label use	187079000
Infection due to Penicillium marneffei	off-label use	372936000
Onychomycosis due to dermatophyte	off-label use	402134005
Heart valve disorder	contraindication	368009	DOID:4079
Hypocalcemia	contraindication	5291005
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Hearing loss	contraindication	15188001
Torsades de pointes	contraindication	31722008
Hypokalemia	contraindication	43339004
Ventricular arrhythmia	contraindication	44103008
Achlorhydria	contraindication	47481007
Chronic heart failure	contraindication	48447003
Hypochlorhydria	contraindication	55961006
Heart failure	contraindication	84114007	DOID:6000
Cardiomyopathy	contraindication	85898001	DOID:0050700
Kidney disease	contraindication	90708001	DOID:557
Prolonged QT interval	contraindication	111975006
Liver function tests abnormal	contraindication	166603001
Hypomagnesemia	contraindication	190855004
Impaired renal function disorder	contraindication	197663003
Disease of liver	contraindication	235856003	DOID:409
Drug-induced hepatitis	contraindication	235876009
Edema	contraindication	267038008
Pregnancy, function	contraindication	289908002
Peripheral nerve disease	contraindication	302226006
Visual impairment	contraindication	397540003
Breastfeeding (mother)	contraindication	413712001
Myocardial ischemia	contraindication	414795007	DOID:3393
Poor metabolizer due to cytochrome p450 CYP2C19 variant	contraindication	424500005
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Dermatophytosis caused by Microsporum canis	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Itrafungol	Virbac AH Inc.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.12	Basic
pKa2	5.0	Basic
pKa3	3.04	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
200MG	ONMEL	SEBELA IRELAND LTD	N022484	April 29, 2010	DISCN	TABLET	ORAL	8486456	Oct. 3, 2028	ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS
65MG	TOLSURA	MAYNE PHARMA	N208901	Dec. 11, 2018	RX	CAPSULE	ORAL	10463740	June 21, 2033	TREATMENT OF FUNGAL INFECTIONS, INCLUDING BLASTOMYCOSIS, HISTOPLASMOSIS, AND ASPERGILLOSIS
65MG	TOLSURA	MAYNE PHARMA	N208901	Dec. 11, 2018	RX	CAPSULE	ORAL	9713642	June 21, 2033	TREATMENT OF FUNGAL INFECTIONS, INCLUDING BLASTOMYCOSIS, HISTOPLASMOSIS, AND ASPERGILLOSIS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	6.05	DRUG MATRIX
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	5.70	CHEMBL
Vasopressin V2 receptor	GPCR	P30518	V2R_HUMAN		IC50	6.10	CHEMBL
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.41	DRUG MATRIX
Lanosterol 14-alpha demethylase	Enzyme	Q16850	CP51A_HUMAN		IC50	5.44	CHEMBL
C-C chemokine receptor type 4	GPCR	P51679	CCR4_HUMAN		IC50	6.70	CHEMBL
C-X-C chemokine receptor type 1	GPCR	P25024	CXCR1_HUMAN		IC50	7	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Ki	6.30	CHEMBL
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase	Enzyme	Q9UNU6	CP8B1_HUMAN		IC50	5.33	CHEMBL
Lanosterol 14-alpha demethylase	Enzyme		CP51_CANAL	INHIBITOR	MIC	9.25	WOMBAT-PK	CHEMBL
Cruzipain	Enzyme		CYSP_TRYCR		IC50	5.52	CHEMBL
14-alpha sterol demethylase Cyp51A	Enzyme		Q4WNT5_ASPFU		Kd	6	CHEMBL
14-alpha sterol demethylase	Enzyme		Q96W81_ASPFM		Kd	7.51	CHEMBL

External reference:

ID	Source
4020560	VUID
N0000148264	NUI
D00350	KEGG_DRUG
4020560	VANDF
C0064113	UMLSCUI
CHEBI:6076	CHEBI
1YN	PDB_CHEM_ID
CHEMBL64391	ChEMBL_ID
CHEMBL1711	ChEMBL_ID
D017964	MESH_DESCRIPTOR_UI
DB01167	DRUGBANK_ID
11426	IUPHAR_LIGAND_ID
5387	INN_ID
304NUG5GF4	UNII
55283	PUBCHEM_CID
28031	RXNORM
4940	MMSL
64593	MMSL
d00102	MMSL
003915	NDDF
387532006	SNOMEDCT_US
96038009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Itraconazole	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5100	CAPSULE	100 mg	ORAL	ANDA	24 sections
itraconazole	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0150	SOLUTION	10 mg	ORAL	NDA	28 sections
itraconazole	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0150	SOLUTION	10 mg	ORAL	NDA	28 sections
itraconazole	HUMAN PRESCRIPTION DRUG LABEL	1	10147-1700	CAPSULE	100 mg	ORAL	NDA	30 sections
itraconazole	HUMAN PRESCRIPTION DRUG LABEL	1	10147-1700	CAPSULE	100 mg	ORAL	NDA	30 sections
Itraconazole	HUMAN PRESCRIPTION DRUG LABEL	1	13668-463	CAPSULE	100 mg	ORAL	ANDA	14 sections
Itraconazole	HUMAN PRESCRIPTION DRUG LABEL	1	13668-463	CAPSULE	100 mg	ORAL	ANDA	14 sections
Itraconazole	HUMAN PRESCRIPTION DRUG LABEL	1	13668-463	CAPSULE	100 mg	ORAL	ANDA	14 sections
Itraconazole	HUMAN PRESCRIPTION DRUG LABEL	1	13668-463	CAPSULE	100 mg	ORAL	ANDA	14 sections
Itraconazole	Human Prescription Drug Label	1	16714-743	CAPSULE, COATED PELLETS	100 mg	ORAL	ANDA	21 sections
Itraconazole	HUMAN PRESCRIPTION DRUG LABEL	1	16729-271	CAPSULE	100 mg	ORAL	ANDA	25 sections
Itraconazole	HUMAN PRESCRIPTION DRUG LABEL	1	16729-271	CAPSULE	100 mg	ORAL	ANDA	25 sections
Itraconazole	Human Prescription Drug Label	1	31722-006	SOLUTION	10 mg	ORAL	ANDA	15 sections
Itraconazole	Human Prescription Drug Label	1	31722-006	SOLUTION	10 mg	ORAL	ANDA	15 sections
ITRACONAZOLE	Human Prescription Drug Label	1	46708-204	CAPSULE	100 mg	ORAL	ANDA	22 sections
ITRACONAZOLE	Human Prescription Drug Label	1	46708-204	CAPSULE	100 mg	ORAL	ANDA	22 sections
Itraconazole	HUMAN PRESCRIPTION DRUG LABEL	1	49884-239	CAPSULE	100 mg	ORAL	ANDA	22 sections
Itraconazole	HUMAN PRESCRIPTION DRUG LABEL	1	50268-450	CAPSULE	100 mg	ORAL	ANDA	13 sections
SPORANOX	HUMAN PRESCRIPTION DRUG LABEL	1	50458-290	CAPSULE	100 mg	ORAL	NDA	29 sections
SPORANOX	HUMAN PRESCRIPTION DRUG LABEL	1	50458-290	CAPSULE	100 mg	ORAL	NDA	29 sections
SPORANOX	HUMAN PRESCRIPTION DRUG LABEL	1	50458-290	CAPSULE	100 mg	ORAL	NDA	29 sections
SPORANOX	HUMAN PRESCRIPTION DRUG LABEL	1	50458-295	SOLUTION	10 mg	ORAL	NDA	28 sections
SPORANOX	HUMAN PRESCRIPTION DRUG LABEL	1	50458-295	SOLUTION	10 mg	ORAL	NDA	28 sections
Tolsura	HUMAN PRESCRIPTION DRUG LABEL	1	51862-462	CAPSULE, GELATIN COATED	65 mg	ORAL	NDA	31 sections
Tolsura	HUMAN PRESCRIPTION DRUG LABEL	1	51862-462	CAPSULE, GELATIN COATED	65 mg	ORAL	NDA	31 sections
Tolsura	HUMAN PRESCRIPTION DRUG LABEL	1	51862-462	CAPSULE, GELATIN COATED	65 mg	ORAL	NDA	31 sections
itraconazole	HUMAN PRESCRIPTION DRUG LABEL	1	59746-282	CAPSULE	100 mg	ORAL	ANDA	17 sections
Itraconazole	HUMAN PRESCRIPTION DRUG LABEL	1	60687-299	CAPSULE	100 mg	ORAL	ANDA	14 sections
Itraconazole	HUMAN PRESCRIPTION DRUG LABEL	1	60687-299	CAPSULE	100 mg	ORAL	ANDA	14 sections
ITRACONAZOLE	Human Prescription Drug Label	1	62332-204	CAPSULE	100 mg	ORAL	ANDA	22 sections